Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Oral Implants Res ; 34(10): 1094-1105, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37483129

ABSTRACT

AIM: To compare subepithelial connective tissue grafts (SCTG) versus guided bone regeneration (GBR) for the treatment of small peri-implant dehiscence defects in terms of profilometric (primary outcome), clinical, and patient-reported outcome measures (PROMs). METHODS: Sixteen patients who presented with small buccal bone dehiscences (≤3 mm) following single implant placement were recruited. Following implant placement, buccal bone defect sites were randomly treated either with a SCTG or GBR. Six patients who lacked bone dehiscences after implant placement were assigned to a negative control. Transmucosal healing was applied in all patients. Patients were examined prior (T1) and after (T2) implant placement, at suture removal (T3), at implant impression (T5), at crown delivery (T6), and 12 (T7) months after crown delivery. Measurements included profilometric outcomes, marginal bone levels, buccal bone and soft tissue thickness, PROMs, and clinical parameters. All data were analyzed descriptively. RESULTS: The median changes in buccal contour as assessed by profilometric measures between T1 and T5 showed a decrease of 1.84 mm for the SCTG group and 1.06 mm for the GBR group. Between T2 and T7, the median change in the buccal contour amounted to 0.45 mm for SCTG and -0.94 mm (=loss) for GBR. Patients' pain perception tended to be higher in SCTG than in GBR. All peri-implant soft tissue parameters showed healthy oral tissues and no clinically relevant differences between groups. CONCLUSION: Within the limitations of this pilot study, treating small peri-implant dehiscence defects with a SCTG might be a viable alternative to GBR. The use of a SCTG tended to result in more stable profilometric outcomes and comparable clinical outcomes to GBR. However, patient-reported outcome measures tended to favor GBR.

3.
J Am Soc Mass Spectrom ; 6(3): 207-11, 1995 Mar.
Article in English | MEDLINE | ID: mdl-24214119

ABSTRACT

Several alkali cation complexes of chiral alkoxymethyl-substituted acylsilanes, prepared in situ by the admixture of alkali iodides to acylsilane sample solutions, were investigated by electrospray ionization-mass spectrometry. Competition experiments suggest that the relative complex stabilities of such species in acetonitrile solution follow the order [Formula: see text], which is different from the order of the relative stabilities of the complexes in the gas phase ([Formula: see text]) as qualitatively determined by a tandem mass spectrometry-type experiment. Additionally, a rough correlation of relative ion responses in the mass spectrometry with relative stereoselectivities-derived from chelate-controlled reactions performed with the respective silanes-was found. The latter observation suggests that the electrospray ionization-mass spectrometry technique is a potentially useful method to predict chemical behavior, and it demands little experimental effort.

4.
J Rheumatol ; 14(1): 55-9, 1987 Feb.
Article in English | MEDLINE | ID: mdl-3106632

ABSTRACT

We reviewed the urinalyses from 2 multicenter controlled randomized trials, one comparing moderate and low dose D-penicillamine to placebo and another comparing gold sodium thiomalate (GSTM), auranofin (AF) and placebo. In the D-penicillamine trial 30% of the 40 patients taking placebo, 34% of the 70 patients receiving 125 mg/day of D-penicillamine and 31% of the 61 patients receiving 500 mg of D-penicillamine had recurrent hematuria. In the GSTM/AF trial, 35% of the 43 placebo treated patients, 35% of the 54 GSTM treated patients and 30% of the 64 AF treated patients had hematuria. No significant difference in the frequency of hematuria between the groups in either trial was apparent. These findings suggest that the traditionally held belief that gold and D-penicillamine cause hematuria should be reconsidered.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Auranofin/therapeutic use , Gold Sodium Thiomalate/therapeutic use , Hematuria/chemically induced , Penicillamine/therapeutic use , Adult , Aged , Arthritis, Rheumatoid/metabolism , Auranofin/adverse effects , Clinical Trials as Topic , Double-Blind Method , Female , Gold Sodium Thiomalate/adverse effects , Hematuria/metabolism , Humans , Male , Middle Aged , Penicillamine/adverse effects , Prospective Studies , Random Allocation
SELECTION OF CITATIONS
SEARCH DETAIL
...